That, in slightly more scientific language, is the big news from a new Lancet analysis: after England rolled out HPV vaccination with very high uptake, cervical cancer deaths in young women fell dramatically - to the point that among women aged 20-24 in 2020-24, no deaths occurred, when about 23 were expected based on earlier trends.[1] For a disease we actually know how to prevent, that is the kind of plot twist public health dreams about.
The virus with a terrible business model
Human papillomavirus, or HPV, is incredibly common. Most infections clear on their own, but some HPV types can linger and, over time, help drive cancers including cervical cancer.[2] It’s a bit like a houseguest who says they’ll just crash for one night and then quietly starts remodeling the kitchen.
That’s why HPV vaccination matters so much. It blocks infection with the high-risk HPV types most strongly linked to cervical cancer. England introduced routine HPV vaccination in 2008 for girls aged 12-13, then added a catch-up campaign for older teens. Coverage was high - around 80-90% before the pandemic.[1]
We’ve already had strong evidence that vaccination cuts HPV infection, precancerous cervical lesions, and cervical cancer incidence.[3,4] But mortality is the hardest endpoint to show, because thankfully it is rarer, and because cancer takes years to develop. You need time, large populations, and the statistical patience of a saint.
The number that makes you sit up
Sasieni and Falcaro looked at cervical cancer deaths in England from 2001 to 2024 in women aged 20-24, 25-29, and 30-34.[1] They compared observed deaths after vaccine rollout with what would have been expected from earlier historical patterns.
The headline result is blunt in the best possible way:
- Women aged 20-24 in 2020-24: 0 observed deaths vs 23.1 expected
- Estimated mortality reduction: 100% in those vaccinated at ages 12-13
- Total cervical cancer deaths prevented up to the end of 2024: about 200[1]
That does not mean cervical cancer has vanished forever, or that every vaccinated person is magically invincible. Observational population studies always come with caveats. But still - zero is a pretty loud number.
And this is where the science gets quietly radical. We often talk about vaccines as preventing infection. This study is about preventing deaths. Not abnormal cells on a slide. Not a graph with a nice downward slope. Actual people who got to stay alive.
This is not just a vaccine story - it’s a systems story
A vaccine can be excellent and still fail if the health system treats access like an exclusive nightclub. England’s result likely depends on something less glamorous than a scientific breakthrough and more annoying to politicians: organized public health.
High uptake did not happen by wishful thinking. It happened because there was a national program, broad delivery, and enough trust and logistics to reach most adolescents.[1] Biology did its part, but infrastructure drove the getaway car.
That matters because the moral of this paper is not “science wins” in some floaty, TED Talk sense. It’s “science wins when people can actually get the intervention.”
Globally, cervical cancer remains a major cause of cancer death, especially in lower-resource settings where vaccination, screening, and treatment are less accessible.[5,6] This is the recurring dark joke in global health: the diseases most preventable on paper often hit hardest where paper plans don’t become real clinics, real nurses, and real follow-up.
Why screening still gets a seat at the table
Even with vaccination, cervical screening still matters. The current vaccines target the biggest troublemakers, but not every cancer-causing HPV type. Plus, many adults were never vaccinated in early adolescence.
So the ideal strategy is not vaccines versus screening. It’s vaccines and screening - prevention with a seatbelt and airbags, because cancer does not award points for minimalism.[2,5]
That broader combination is exactly what the WHO has pushed in its plan to eliminate cervical cancer as a public health problem.[5] This new mortality signal from England suggests that goal is not naive. It’s hard, uneven, and politically vulnerable - but not fantasy.
The catch nobody should ignore
There’s one big caution label here. England achieved this with high coverage in a robust health system. Many countries have not. Some still struggle with vaccine cost, delivery, misinformation, workforce shortages, or screening gaps.[5,6]
So if you read a triumphant headline and think, “Great, problem solved,” not quite. A prevention tool only protects the people it reaches. The real ethical question is whether this kind of outcome becomes a shared public good or a luxury item with better branding.
And that, honestly, is the least glamorous part of cancer prevention. No one throws a parade for supply chains. But supply chains save lives anyway.
The bottom line
This study offers some of the clearest national-level evidence yet that HPV vaccination is linked to a sharp drop in cervical cancer mortality in young women in England.[1] For those vaccinated at 12-13, the effect looks especially striking.
Which is both thrilling and a little maddening. Thrilling because prevention is working. Maddening because it reminds us how many deaths are avoidable when health systems decide to act like prevention is a priority rather than a nice idea for a brochure.
The science here is excellent. The challenge now is social, political, and stubbornly practical: make this protection ordinary everywhere.
References
-
Sasieni P, Falcaro M. Cervical cancer mortality trends following HPV vaccination in England, 2001-24: an analysis of population-based mortality data. Lancet. 2026. doi:10.1016/S0140-6736(26)00918-9
-
National Cancer Institute. Human Papillomavirus (HPV) Vaccines. Available from: https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-vaccine-fact-sheet
-
Falcaro M, Castañon A, Ndlela B, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet. 2021;398(10316):2084-2092. doi:10.1016/S0140-6736(21)02178-4
-
Lei J, Ploner A, Elfström KM, et al. HPV Vaccination and the Risk of Invasive Cervical Cancer. N Engl J Med. 2020;383(14):1340-1348. doi:10.1056/NEJMoa1917338
-
World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Available from: https://www.who.int/publications/i/item/9789240014107
-
Brisson M, Kim JJ, Canfell K, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395(10224):575-590. doi:10.1016/S0140-6736(20)30068-4
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.